Rukobia (fostemsavir)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- fostemsavir
- Company
- ViiV Healthcare B.V.
- Status
- Authorised
- Therapeutic area
- HIV Infections
- CHMP opinion
- Thu 10 Dec 2020
- EU approval
- Thu 04 Feb 2021
- Designations
- Additional monitoring
- Application
- EMEA/H/C/005011
- ATC
- J05AX
- Official record
- www.ema.europa.eu
Indication
Rukobia, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.
Regulatory milestones
No milestones recorded in the last year.
Follow Rukobia
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.